Table 3.

Included studies which reported access to treatment defined as treatment receipt and utilisation (n = 15)

Author (year)	Outcome of interest	Type of SACT treatment	Main finding(s)
Accordino et al. (2017) [26]	Receipt of EOL care which included receipt of IV chemotherapy within the last 14 days of life	IV chemotherapy as treatment within the last 14 days of life	60% receipt of IV chemotherapy as treatment within the last 14 days of life
Alves et al. (2022) [33]	Receipt of no SACT treatment	Unspecified SACT	60% of women received no first-course treatment
Cole et al. (2019) [34]	Receipt of specialist palliative care (SPC) which included non-curative systemic chemotherapy	Non-curative systemic chemotherapy	18.5% received specialist palliative care (SPC) which included non-curative systemic chemotherapy
Falchook et al. (2017) [35]	Receipt of chemotherapy within the last 14 days of life	Chemotherapy within the last 14 days of life	14.1% received chemotherapy within the last 14 days of life
Giap et al. (2023) [27]	Receipt of palliative care which included non-curative systemic therapy	Non-curative systemic chemotherapy	21.4% received non-curative systemic chemotherapy
Sathe et al. (2023) [28]	Receipt of cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors following secondary (metastatic) breast cancer diagnosis	Cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors	76.3% received CDK4/6i
Shih et al. (2009) [39]	Receipt of immunotherapy post diagnosis	Immunotherapy	4% received immunotherapy post diagnosis
Shiovitz et al. (2015) [40]	Utilisation of cancer-directed therapy which included chemotherapy	Chemotherapy	61% received SACT
Skinner et al. (2021) [32]	Receipt of systemic anticancer therapy	Unspecified SACT	83% received SACT
Small et al. (2012) [41]	Receipt of no first course anticancer therapy	Unspecified SACT—no first-course therapy	12.8% received no first-course SACT therapy
Statler et al. (2019) [30]	First-line treatment with chemotherapy and/or hormone therapy	First-line treatment with chemotherapy and/or hormone therapy	60% received first-line treatment with hormone therapy, 39% received chemotherapy, and 42% of patients received anti-HER2 therapy
Vyas et al. (2021) [5]	Receipt of initial systemic therapy within 6 months of secondary (metastatic) breast cancer diagnosis	Unspecified systemic anticancer therapy	72.3% received initial (guideline concordant) systemic therapy within 6 months of secondary (metastatic) breast cancer diagnosis
Wan & Jubelirer (2015) [35]	Receipt of chemotherapy within 6 months of diagnosis	Chemotherapy	30.2% received chemotherapy
Wang & Du (2015) [42]	Receipt of hormone therapy 1 year post initiation (stratified by chemotherapy use)	Hormone (endocrine) therapy	70.8% received hormone therapy
Wolfson et al. (2015) [43]	Receipt of care which included un specified SACT SACT at a National Cancer Institute Comprehensive Cancer Centre (NCI CCC)	Nonspecified SACT	**22–39 years 9.7% 40–65 years 90.3%